US EditionPublished • loading... • Updated
Slimmer Prices Planned for Weight Loss Drugs in 2026
The deal will lower monthly costs from over $1,000 to as low as $250 within two years, using a most-favored-nation pricing strategy, officials said.
- President Donald Trump announced he brokered a deal with Novo Nordisk to lower GLP-1 drug prices, with direct sales via TrumpRx.gov expected by the end of 2025.
- The administration's 'most-favored-nation' pricing initiative aims to bring U.S. drug costs in line with other developed countries as part of a broader push to lower drug prices.
- For direct buyers, TrumpRx will charge about $350 per month initially, with retail prices at warehouse stores like Sam's Club and Costco at $499 and some GLP-1s exceeding $1,000, while Trump officials flagged a GLP-1 pill priced at $149.
- Medicare users will likely have to wait until mid-2026 for price changes, and a health policy professor at Vanderbilt University notes Medicare cannot cover GLP-1s for weight loss without a law change, though temporary pilot programs may test changes.
- Experts say lower prices could boost demand as about 1 in 9 Americans used a GLP-1 in 2025 and 14% are interested, though Eli Lilly warns commercial insurance plans may limit coverage.
Insights by Ground AI
Podcasts & Opinions
53 Articles
53 Articles
ABC FOX Montana+51 Reposted by 51 other sources
Slimmer Prices Planned for Weight Loss Drugs in 2026
People taking GLP-1 meds could see costs drop in 2026, thanks to a new federal deal with Eli Lilly and Novo Nordisk, the makers of Ozempic, Wegovy, Mounjaro and Zepbound. If you’re paying cash for a GLP-1, prices will fall…
·Missoula, United States
Read Full Article
Coverage Details
Total News Sources53
Leaning Left7Leaning Right7Center11Last UpdatedBias Distribution44% Center
Bias Distribution
- 44% of the sources are Center
44% Center
L 28%
C 44%
R 28%
Factuality
To view factuality data please Upgrade to Premium
